Wednesday, traders were re-assessing what this pandemic outbreak will mean for the North American economy (and the consensus of their through is, it won’t be pretty). Nonetheless, a couple of firms in the health field trumpeted news uplifting to both share prices and spirits.
Belgrade, Montana-headquartered Lattice Biologics Ltd. (TSX-Venture:LBL), but which trades on the TSX Venture Exchange, has reportedly re-priced the strike price of the three million stock options originally to be granted to Directors and Employees announced in March to $.095 from $.075 due to recent market activity. The options will have an exercise term of five years from the date of grant.
Lattice Biologics develops and manufactures biologic products to domestic and international markets. The Company’s products are used in a variety of surgical applications.
Lattice Biologics maintains its headquarters, laboratory and manufacturing facilities in Belgrade, Montana as well as offices in Phoenix, Arizona. The facility includes ISO Class 1000 and ISO Class 100 clean rooms, and specialized equipment capable of crafting traditional allografts and precision specialty allografts for various clinical applications
LBL shares hurtled higher Wednesday 1.5 cents, or 15.8%, to 11 cents, on volume of 1.6 million shares.
Meanwhile, Miami-based Progressive Care Inc. (OTC:RXMD), a personalized health-care services and technology company, is pleased to announce operational performance data for March, which featured breakthrough growth in total sales and a new Company record in total number of prescriptions filled on sharp market share gains:
Progressive reported Consolidated monthly gross sales across all locations totaled $3.6 million, representing year-over-year growth of 105% compared to March 2019. The company also reported prescriptions filled during the month came in at 47,467, representing year-over-year growth of 76%.
Enthused CEO Parikh Mars, "Our market-leading contactless delivery experience has positioned Progressive Care to truly thrive in this uniquely challenging context, and that really showed through in March,
"Much of this growth is the result of patients and physicians choosing our pharmacies over grocery store and chain pharmacies to better protect themselves from exposure during this time. We have worked steadily to deliver prescriptions securely while adhering to contactless protocols during the pandemic."
Shares in RXMD grew 0.25 cents, or 6.9%, to 3.85 cents, on volume of 500,000 shares.
Related Stories
